Friday, April 13, 2018 10:14:57 PM
Stem cells are cells that can differentiate into different cell types of the body (becoming different tissue cell types, including different stem cell types) according to the body's developmental programming (DNA and CNS, cellular chemical and electromagnetic environments, etc.)
Adult stem cells can be harvested from bone marrow, blood, umbilical cord, and adipose (fat) tissues. Most of the human organs and tissues cannot regenerate except for blood, intestine lining, etc. but under technological interventions ("coercions") they could be used to generate replacement cells/tissues to treat diseases. So, this type of medical technology is on the forefront of medicine.
We could call this technology "cellular genesis" since it is rebuilding tissues when they need to be strengthened, or where cells need to be repopulated, not autonomously like cancers, but under the influences and controls of local tissue environments. It may be decades before we even understand how everything works together for a fertilized egg to develop into an organism, but right now we know this company has something that works to treat many diseases. This company represents Basic Science and Medical Technology.
Plus, there are literally hundreds of different cell types in our bodies. One major benefit of using stem cells is that there would be no host rejection. Actually, no host-donor matching is needed with amniotic stem cells that the company has developed. Therefore, the potential of CELZ is huge!
Great CEO, great team of scientists, great technologies, great institutes and associations and partnerships, increasing revenues, many pipelines, multiple areas of research and developments, no toxic loans!
I see multi-billion dollar potential for CELZ within 5-10 years (though a little optimistic), but many on this board would lose out because they sell too early to make a profit. That's why big board stock rewards are only for those who have patience and investment insights (I am not claiming either:)!
JMHO
Recent CELZ News
- Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment • GlobeNewswire Inc. • 11/13/2024 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2024 09:45:23 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/08/2024 09:06:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/04/2024 09:01:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2024 08:23:39 PM
- Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/16/2024 04:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2024 08:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM